Amgen

AMGNNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$212.555 B

$393.16 +1.95%

Close of 21 Sept 2026

Revenue

$36.8B

#119 by revenue

Earnings

$7.71B

#61 by earnings

Shares outstanding

540,632,005

Latest filing cover page

P/E ratio

27.6

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#1AmgenAMGN$212.6B
#2Gilead SciencesGILD$186.7B
#3ModernaMRNA$69.0B
#4Argenx SeARGX$61.3B
#5Revolution MedicinesRVMD$41.3B

What if Amgen were worth as much as…

Open the what-if tool →

Gold $30.3T

$55,997.52

Per share 142× higher

Bitcoin $1.72T

$3,181.10

Per share 8.09× higher

Nvidia $5.48T

$10,136.02

Per share 25.8× higher

Or at a round number

$500.0B $1.00T $2.00T $5.00T

Where these numbers come from

Share counts and financials for Amgen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.